Arvinas Shares Soar 7.00% on Divergent Analyst Ratings $100M Buyback Boost

The share price rose to its highest level this month today, with an intraday gain of 7.00%.

Arvinas’ stock has been shaped by divergent analyst ratings, with Barclays raising its price target to $16 on Nov. 6, while Goldman Sachs downgraded to “sell” on Oct. 15. The average analyst rating remains “Hold” with a $16.39 target. Q3 2025 earnings showed revenue of $41.9 million, exceeding estimates but declining 59.1% year-over-year. A $100 million share buyback program and insider purchases signal management’s confidence in undervaluation.

Institutional investors increased stakes significantly in Q1-Q3 2025, with 95.19% of shares held by funds. Arvinas, focused on protein degradation therapies, faces high volatility (beta of 2.38) but attracts interest for its long-term potential. While revenue declines and negative margins persist, strategic actions and institutional backing highlight a mix of optimism and caution for the clinical-stage biotech.